Verma Amit, Deb Dilip K, Sassano Antonella, Uddin Shahab, Varga John, Wickrema Amittha, Platanias Leonidas C
Section of Hematology-Oncology, Department of Medicine, University of Illinois at Chicago and West Side Veterans Affairs Medical Center, Chicago, Illinois 60607, USA.
J Biol Chem. 2002 Mar 8;277(10):7726-35. doi: 10.1074/jbc.M106640200. Epub 2001 Dec 31.
Type I interferons (IFNs) are potent regulators of normal hematopoiesis in vitro and in vivo, but the mechanisms by which they suppress hematopoietic progenitor cell growth and differentiation are not known. In the present study we provide evidence that IFN alpha and IFN beta induce phosphorylation of the p38 mitogen-activated protein (Map) kinase in CD34+-derived primitive human hematopoietic progenitors. Such type I IFN-inducible phosphorylation of p38 results in activation of the catalytic domain of the kinase and sequential activation of the MAPK-activated protein kinase-2 (MapKapK-2 kinase), indicating the existence of a signaling cascade, activated downstream of p38 in hematopoietic progenitors. Our data indicate that activation of this signaling cascade by the type I IFN receptor is essential for the generation of the suppressive effects of type I IFNs on normal hematopoiesis. This is shown by studies demonstrating that pharmacological inhibitors of p38 reverse the growth inhibitory effects of IFN alpha and IFN beta on myeloid (colony-forming granulocytic-macrophage) and erythroid (burst-forming unit-erythroid) progenitor colony formation. In a similar manner, transforming growth factor beta, which also exhibits inhibitory effects on normal hematopoiesis, activates p38 and MapKapK-2 in human hematopoietic progenitors, whereas pharmacological inhibitors of p38 reverse its suppressive activities on both myeloid and erythroid colony formation. In further studies, we demonstrate that the primary mechanism by which the p38 Map kinase pathway mediates hematopoietic suppression is regulation of cell cycle progression and is unrelated to induction of apoptosis. Altogether, these findings establish that the p38 Map kinase pathway is a common effector for type I IFN and transforming growth factor beta signaling in human hematopoietic progenitors and plays a critical role in the induction of the suppressive effects of these cytokines on normal hematopoiesis.
I型干扰素(IFN)在体外和体内都是正常造血的有效调节因子,但其抑制造血祖细胞生长和分化的机制尚不清楚。在本研究中,我们提供证据表明,IFNα和IFNβ可诱导源自CD34 +的原始人类造血祖细胞中p38丝裂原活化蛋白(Map)激酶的磷酸化。这种I型IFN诱导的p38磷酸化导致激酶催化结构域的激活以及MAPK活化蛋白激酶2(MapKapK-2激酶)的顺序激活,表明存在一个信号级联反应,在造血祖细胞中p38下游被激活。我们的数据表明,I型IFN受体激活该信号级联反应对于I型IFN对正常造血产生抑制作用至关重要。研究表明,p38的药理抑制剂可逆转IFNα和IFNβ对髓系(集落形成粒细胞 - 巨噬细胞)和红系(爆式形成单位 - 红系)祖细胞集落形成的生长抑制作用,从而证明了这一点。以类似的方式,对正常造血也表现出抑制作用的转化生长因子β可激活人类造血祖细胞中的p38和MapKapK-2,而p38的药理抑制剂可逆转其对髓系和红系集落形成的抑制活性。在进一步的研究中,我们证明p38 Map激酶途径介导造血抑制的主要机制是细胞周期进程的调节,与细胞凋亡的诱导无关。总之,这些发现表明p38 Map激酶途径是I型IFN和转化生长因子β信号在人类造血祖细胞中的共同效应器,并在诱导这些细胞因子对正常造血的抑制作用中起关键作用。